KRAS and cancer: Cells with a low KRAS4A/KRAS4B ratio have shown higher sensitivity to cancer treatment drugs and an association with high KRAS signaling and a poor patient outcome, suggesting that they could serve as biomarkers of sensitivity to existing cancer treatments [107, 108].